$Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study$
QR Code

Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study

Saved in:

Bibliographic Details
Published in:	Hematological oncology Vol. 41; no. S2; pp. 571 - 572
Main Authors:	Wang, M. L., Mei, M., Barr, P. M., Barrientos, J. C., Vos, S., Furman, R. R., Patel, K., Wierda, W. G., Choi, M. Y., Kallam, A., Wang, S., Ogbu, U. C., Marinello, P., Spurgeon, S. E.
Format:	Journal Article
Language:	English
Published:	Chichester Wiley Subscription Services, Inc 01-06-2023
Subjects:	Lymphoma Non-Hodgkin's lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	0278-0232 1099-1069
DOI:	10.1002/hon.3164_427